$MTEM
Molecular Templates, Inc.

2018 Q4 Form 10-K Financial Statement

#000156459019010145 Filed on March 29, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2018 2017 Q4
Revenue $4.680M $13.29M $820.0K
YoY Change 470.73% 291.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.920M $14.08M $3.520M
YoY Change 11.36% 19.73% 80.51%
% of Gross Profit
Research & Development $7.560M $30.20M $4.660M
YoY Change 62.23% 218.25% 54.82%
% of Gross Profit
Depreciation & Amortization $400.0K $974.0K $90.00K
YoY Change 344.44% 528.39% 350.0%
% of Gross Profit
Operating Expenses $11.48M $44.28M $8.180M
YoY Change 40.34% 108.49% 64.92%
Operating Profit -$31.00M
YoY Change
Interest Expense $160.0K $710.0K $350.0K
YoY Change -54.29% -16.76% 775.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.630M -$30.29M -$6.920M
YoY Change -4.19% 30.9% 88.04%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.630M -$30.29M -$6.920M
YoY Change -4.19% 30.89% 87.94%
Net Earnings / Revenue -141.67% -227.98% -843.9%
Basic Earnings Per Share
Diluted Earnings Per Share -$180.8K -$1.023M -$257.4K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $97.96M $98.00M $58.91M
YoY Change 66.28% 66.38% 3365.29%
Cash & Equivalents $87.72M $87.70M $58.91M
Short-Term Investments $10.23M $10.20M $0.00
Other Short-Term Assets $95.00K $2.300M $19.00K
YoY Change 400.0% 53.33% 171.43%
Inventory
Prepaid Expenses $2.244M $1.485M
Receivables $200.0K $200.0K
Other Receivables $4.400M $4.400M
Total Short-Term Assets $104.9M $104.9M $60.41M
YoY Change 73.57% 73.68% 3178.02%
LONG-TERM ASSETS
Property, Plant & Equipment $6.851M $6.900M $1.952M
YoY Change 250.97% 245.0% 484.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change
Other Assets $1.821M $1.800M $1.402M
YoY Change 29.89% 28.57%
Total Long-Term Assets $35.30M $35.30M $29.98M
YoY Change 17.74% 17.67% 33.59%
TOTAL ASSETS
Total Short-Term Assets $104.9M $104.9M $60.41M
Total Long-Term Assets $35.30M $35.30M $29.98M
Total Assets $140.2M $140.2M $90.39M
YoY Change 55.06% 55.09% 272.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $780.0K $800.0K $2.517M
YoY Change -69.01% -68.0% 206.2%
Accrued Expenses $5.357M $5.400M $2.690M
YoY Change 99.14% 100.0% 202.93%
Deferred Revenue $26.23M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $2.400M
YoY Change -100.0% 0.0%
Total Short-Term Liabilities $32.51M $32.50M $10.44M
YoY Change 211.33% 212.5% -24.14%
LONG-TERM LIABILITIES
Long-Term Debt $3.254M $3.300M $1.078M
YoY Change 201.86% 200.0% -65.94%
Other Long-Term Liabilities $819.0K $3.500M $628.0K
YoY Change 30.41% 118.75% 1084.91%
Total Long-Term Liabilities $4.073M $6.800M $1.706M
YoY Change 138.75% 151.85% -46.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.51M $32.50M $10.44M
Total Long-Term Liabilities $4.073M $6.800M $1.706M
Total Liabilities $39.25M $39.30M $13.10M
YoY Change 199.59% 200.0% -23.07%
SHAREHOLDERS EQUITY
Retained Earnings -$94.70M -$64.47M
YoY Change 46.89% 59.69%
Common Stock $195.6M $141.8M
YoY Change 37.99% 24857.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $100.9M $100.9M $77.29M
YoY Change
Total Liabilities & Shareholders Equity $140.2M $140.2M $90.39M
YoY Change 55.06% 55.09% 2817.72%

Cashflow Statement

Concept 2018 Q4 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$6.630M -$30.29M -$6.920M
YoY Change -4.19% 30.89% 87.94%
Depreciation, Depletion And Amortization $400.0K $974.0K $90.00K
YoY Change 344.44% 528.39% 350.0%
Cash From Operating Activities $19.39M -$4.465M -$7.910M
YoY Change -345.13% -68.7% 853.01%
INVESTING ACTIVITIES
Capital Expenditures -$300.0K $5.722M -$730.0K
YoY Change -58.9% 419.71% 942.86%
Acquisitions
YoY Change
Other Investing Activities -$10.22M -$10.22M $0.00
YoY Change -194.45% -100.0%
Cash From Investing Activities -$10.53M -$15.95M -$730.0K
YoY Change 1342.47% -264.13% 151.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $48.05M
YoY Change -16.64%
Debt Paid & Issued, Net $3.605M
YoY Change 50.21%
Cash From Financing Activities 110.0K 49.22M -630.0K
YoY Change -117.46% -20.28% -152.07%
NET CHANGE
Cash From Operating Activities 19.39M -4.465M -7.910M
Cash From Investing Activities -10.53M -15.95M -730.0K
Cash From Financing Activities 110.0K 49.22M -630.0K
Net Change In Cash 8.970M 28.81M -9.270M
YoY Change -196.76% -49.63% -10400.0%
FREE CASH FLOW
Cash From Operating Activities $19.39M -$4.465M -$7.910M
Capital Expenditures -$300.0K $5.722M -$730.0K
Free Cash Flow $19.69M -$10.19M -$7.180M
YoY Change -374.23% -33.7% 844.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32509000
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87721000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58910000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
10234000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2244000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1485000
CY2018Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
240000
CY2017Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
0
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4424000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
19000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
104863000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
60414000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6851000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1952000
CY2018Q4 mtem In Process Research And Development
InProcessResearchAndDevelopment
26623000
CY2017Q4 mtem In Process Research And Development
InProcessResearchAndDevelopment
26623000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1821000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1402000
CY2018Q4 us-gaap Assets
Assets
140158000
CY2017Q4 us-gaap Assets
Assets
90391000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
780000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2517000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5357000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3254000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2690000
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2400000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
26231000
CY2017Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
954000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10442000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2765000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
141000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
70000
CY2018Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
3000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2670000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1078000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
816000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
628000
CY2018Q4 us-gaap Liabilities
Liabilities
39252000
CY2017Q4 us-gaap Liabilities
Liabilities
13102000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
195573000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
141733000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94704000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-64471000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
100906000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
77289000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
140158000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
90391000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13285000
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3395000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30202000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11755000
CY2018 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
990000
CY2017 mtem Interest And Other Expense Net
InterestAndOtherExpenseNet
853000
CY2018 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
951000
CY2017 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
128000
CY2018 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
CY2017 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
4619000
CY2018 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0
CY2017 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
958000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30287000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24098000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.02
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.11
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29601692
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11400881
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30287000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-39805000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
61000
CY2017 mtem Deemed Dividends On Preferred Stock
DeemedDividendsOnPreferredStock
958000
CY2017 mtem Preferred Stock Carrying Value Transferred To Common And Apic
PreferredStockCarryingValueTransferredToCommonAndAPIC
26829000
CY2017 mtem Stock Issued During Period Value Conversion Of Preferred Stock Warrants To Common Stock
StockIssuedDuringPeriodValueConversionOfPreferredStockWarrantsToCommonStock
87000
CY2017 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
15105000
CY2017 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
39670000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57648000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1792000
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
283000
CY2018 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1522000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48053000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3992000
CY2018 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
54000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3800000
CY2017 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2400000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
974000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
3992000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
318000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
342000
CY2018 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
951000
CY2017 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
128000
CY2018 us-gaap Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
39000
CY2018 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
125000
CY2017 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
0
CY2018 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-115000
CY2017 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-4619000
CY2018 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-35000
CY2017 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
410000
CY2017 us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
4351000
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
12000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
450000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
81000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1209000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
155000
CY2018 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
88000
CY2017 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
20000
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
318000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
26136000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
895000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4465000
CY2018 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0
CY2017 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
11216000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1101000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
CY2018 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
0
CY2017 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
400000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48053000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9715000
CY2018 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
47000
CY2017 us-gaap Repayments Of Debt And Capital Lease Obligations
RepaymentsOfDebtAndCapitalLeaseObligations
43000
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4537000
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3605000
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2400000
CY2018 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0
CY2017 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
208000
CY2018 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2017 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2685000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61000
CY2018 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2017 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
4000000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57648000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61743000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28811000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
57194000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1716000
CY2018 mtem Non Cash Deemed Dividends On Preferred Stock
NonCashDeemedDividendsOnPreferredStock
0
CY2017 mtem Non Cash Deemed Dividends On Preferred Stock
NonCashDeemedDividendsOnPreferredStock
958000
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
CY2017 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
26829000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
10486000
CY2018 mtem Noncash Conversion Of Warrant Liability Amount Converted
NoncashConversionOfWarrantLiabilityAmountConverted
0
CY2017 mtem Noncash Conversion Of Warrant Liability Amount Converted
NoncashConversionOfWarrantLiabilityAmountConverted
87000
CY2018 mtem Non Cash Capital Lease Additions To Fixed Assets
NonCashCapitalLeaseAdditionsToFixedAssets
0
CY2017 mtem Non Cash Capital Lease Additions To Fixed Assets
NonCashCapitalLeaseAdditionsToFixedAssets
291000
CY2018 mtem Non Cash Fixed Asset Additions In Accounts Payable
NonCashFixedAssetAdditionsInAccountsPayable
0
CY2017 mtem Non Cash Fixed Asset Additions In Accounts Payable
NonCashFixedAssetAdditionsInAccountsPayable
382000
CY2018 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:2.68%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts in the prior year&#8217;s presentations have been reclassified to conform to the current presentation.&nbsp;&nbsp;These reclassifications had no effect on previously reported net loss.</p>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.72%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America as defined by the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. </p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.72%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s cash, cash equivalents and marketable securities are with two major financial institutions in the United States. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners&#8217; financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company&#8217;s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Takeda Pharmaceutical Company Ltd. (&#8220;Takeda&#8221;). Approximately 53% and 56% of total revenues for the year ended December 31, 2018 and 2017, were derived from Takeda. See also Note 4, Research and Development Collaboration Agreements, regarding the collaboration agreements with Takeda.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug candidates developed by the Company may require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#8217;s drug candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p>
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
51751000
CY2017Q3 mtem Number Of Issued And Outstanding Shares Of Common Stock Converted Into One Issued And Outstanding Share Of Common Stock
NumberOfIssuedAndOutstandingSharesOfCommonStockConvertedIntoOneIssuedAndOutstandingShareOfCommonStock
11
CY2017Q3 mtem Number Of Issued And Outstanding Shares Of Common Stock Converted By Every Eleven Shares Of Issued And Outstanding Common Stock
NumberOfIssuedAndOutstandingSharesOfCommonStockConvertedByEveryElevenSharesOfIssuedAndOutstandingCommonStock
1
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2017 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
6395000
CY2017 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-15599000
CY2018 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
7283000
CY2017 mtem Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
2408000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
95668000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10234000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2018 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2017 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
3300000
CY2017Q4 us-gaap Long Term Debt
LongTermDebt
3500000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8184000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2364000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1333000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
412000
CY2018 us-gaap Depreciation
Depreciation
958000
CY2017 us-gaap Depreciation
Depreciation
155000
CY2018Q4 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
297000
CY2017Q4 mtem Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
374000
CY2018Q4 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
598000
CY2017Q4 mtem Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
702000
CY2018Q4 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
2644000
CY2017Q4 mtem Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
435000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1787000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1149000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
31000
CY2018Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
33000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
30000
CY2018Q4 us-gaap Deferred Revenue
DeferredRevenue
28901000
CY2017Q4 us-gaap Deferred Revenue
DeferredRevenue
2765000
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.98
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.70
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
20.83
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.43
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.43
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1266000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1193000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1222000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1247000
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
17473
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
235808
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2768711
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1844787
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
407682
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
202817
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4002999
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4002999
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
499000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
33000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
21000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
54000
CY2018Q4 us-gaap Capital Leases Future Minimum Payments Interest Included In Payments
CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments
4000
CY2018Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
50000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1607856
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.92
CY2017 mtem Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Merger Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInMergerWeightedAverageExercisePrice
33.62
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.30
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.66
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
35.48
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.07
CY2018Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
17000
CY2016Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
25871000
CY2017 us-gaap Temporary Equity Accretion Of Dividends
TemporaryEquityAccretionOfDividends
958000
CY2017 mtem Conversion Of Preferred Stock In To Common Stock Upon Merger
ConversionOfPreferredStockInToCommonStockUponMerger
-26829000
CY2017Q4 us-gaap Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
0
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3331735
CY2018 mtem Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
190000
CY2018 mtem Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
0
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3521735
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
941684
CY2017 mtem Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Assumed In Merger
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAssumedInMerger
963681
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1116627
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
15.19
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y8M12D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M6D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y4M24D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y8M12D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
900000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11000000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1500000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1500000
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1500000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2600000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
78000
CY2018 mtem Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options1
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions1
0
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3992000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1792000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13000000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M24D
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2017 mtem Tax Cuts And Jobs Act Of2017 Change In Tax Rate Change In Valuation Allowance Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateChangeInValuationAllowanceIncomeTaxExpenseBenefit
6863000
CY2017 mtem Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpenseBenefit
6900000
CY2017 mtem Tax Cuts And Jobs Act Of2017 Measurement Period Adjustment Income Tax Expense Benefit
TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6361000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7867000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-69000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-21000
CY2018 mtem Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
-24000
CY2017 mtem Income Tax Reconciliation Permanent Differences
IncomeTaxReconciliationPermanentDifferences
87000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
608000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
237000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2758000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4766000
CY2018 mtem Income Tax Reconciliation Acquisition Related Permanent Differences
IncomeTaxReconciliationAcquisitionRelatedPermanentDifferences
0
CY2017 mtem Income Tax Reconciliation Acquisition Related Permanent Differences
IncomeTaxReconciliationAcquisitionRelatedPermanentDifferences
2281000
CY2018 mtem Income Tax Reconciliation Expiring State Carryovers And Other
IncomeTaxReconciliationExpiringStateCarryoversAndOther
4304000
CY2017 mtem Income Tax Reconciliation Expiring State Carryovers And Other
IncomeTaxReconciliationExpiringStateCarryoversAndOther
991000
CY2018 mtem Tax Cuts And Jobs Act Of2017 Change In Tax Rate Change In Valuation Allowance Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateChangeInValuationAllowanceIncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
6863000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19941000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13797000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2049000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
5060000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4547000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4058000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
210000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
581000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
404000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
254000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
27151000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23750000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
925000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
282000
CY2018Q4 mtem Deferred Tax Liabilities Research And Development Intangible Assets
DeferredTaxLiabilitiesResearchAndDevelopmentIntangibleAssets
5591000
CY2017Q4 mtem Deferred Tax Liabilities Research And Development Intangible Assets
DeferredTaxLiabilitiesResearchAndDevelopmentIntangibleAssets
5591000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
6516000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
5873000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20635000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
17877000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2800000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1143000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2018 mtem Unrecognized Tax Benefits Increases Decreases Resulting From Acquisition
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromAcquisition
-1143000
CY2017 mtem Unrecognized Tax Benefits Increases Decreases Resulting From Acquisition
UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromAcquisition
1064000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
79000
CY2018Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001564590-19-010145-index-headers.html Edgar Link pending
0001564590-19-010145-index.html Edgar Link pending
0001564590-19-010145.txt Edgar Link pending
0001564590-19-010145-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g1yaz0koiono000001.jpg Edgar Link pending
g1yaz0koiono000002.jpg Edgar Link pending
g1yaz0koiono000003.jpg Edgar Link pending
g1yaz0koiono000004.jpg Edgar Link pending
g1yaz0koiono000005.jpg Edgar Link pending
g1yaz0koiono000006.jpg Edgar Link pending
gm2cugnqw2ux000001.jpg Edgar Link pending
gm2cugnqw2ux000002.jpg Edgar Link pending
gm2cugnqw2ux000003.jpg Edgar Link pending
mtem-10k_20181231.htm Edgar Link pending
mtem-20181231.xml Edgar Link completed
mtem-20181231.xsd Edgar Link pending
mtem-20181231_cal.xml Edgar Link unprocessable
mtem-20181231_def.xml Edgar Link unprocessable
mtem-20181231_lab.xml Edgar Link unprocessable
mtem-20181231_pre.xml Edgar Link unprocessable
mtem-ex1037_253.htm Edgar Link pending
mtem-ex103_252.htm Edgar Link pending
mtem-ex211_6.htm Edgar Link pending
mtem-ex231_8.htm Edgar Link pending
mtem-ex311_11.htm Edgar Link pending
mtem-ex312_18.htm Edgar Link pending
mtem-ex321_17.htm Edgar Link pending
mtem-ex322_15.htm Edgar Link pending
mtem-ex34_311.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending